Mimetogen Pharmaceuticals USA, Inc.   Report issue

For profit Phase 3
Founded: Montreal Canada (2004)

Organization Overview

First Clinical Trial
2010
NCT01257607
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Mimetogen Pharmaceuticals USA, Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

tavilermide (6 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dry Eye Syndromes (Phase 3)

Eye Diseases (Phase 3)

Keratoconjunctivitis (Phase 3)

Keratoconjunctivitis Sicca (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 6
  • # of Trial APIs: 1